Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.42
  • Today's Change-0.059 / -12.41%
  • Shares traded2.04m
  • 1 Year change+35.48%
  • Beta0.8208
Data delayed at least 15 minutes, as of Mar 03 2026 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The Company has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). It has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.

  • Revenue in EUR (TTM)3.32m
  • Net income in EUR-27.06m
  • Incorporated1996
  • Employees11.00
  • Location
    Nicox SADrakkar 2 - Batiment D2405 route des DolinesCS 10313 Sophia AntipolisBIOT 06410FranceFRA
  • Phone+33 497245300
  • Fax+33 497245399
  • Websitehttps://www.nicox.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aelis Farma SA446.00k-8.20m18.50m26.00--3.03--41.49-0.5998-0.59980.03260.44610.0247--0.582617,153.85-45.48-24.79-64.80-40.70-----1,837.89-115.10----0.4907---70.42---46.83--39.47--
Advicenne SA-100.00bn-100.00bn30.68m15.00---------------1.95-----------61.16---123.11---258.05---431.560.4485------4.769.6314.14------
SMAIO SA8.28m-1.85m39.52m43.00--5.33--4.77-0.3498-0.34981.551.310.62650.92147.47202,030.50-14.00-10.92-17.52-20.2383.8383.68-22.35-31.592.50-32.370.288--2.1269.74-426.41--16.09--
NicOx SA3.32m-27.06m42.41m11.00------12.79-0.3657-0.36570.045-0.06590.1034--1.63663,166.00-84.36-28.03-91.95-30.66-----816.13-338.04---56.801.48--13.852.77-7.22------
Valerio Therapeutics SA1.83m-13.17m74.42m25.00------40.67-0.0914-0.09140.012-0.05910.0735--0.402648,157.89-52.95-33.39-145.21-42.4759.3478.97-720.27-631.62---17.09-----0.3889-16.01-17.57--65.11--
AB Science SA1.03m-8.54m86.04m37.00------83.78-0.1478-0.14780.0178-0.4570.04650.44297.9326,333.33-38.64-52.12-206.63-332.2290.7593.25-831.45-1,016.800.668-4.96----10.52-7.3634.66---16.85--
Euroapi SA882.80m-124.30m197.68m3.43k--0.2065--0.2239-1.31-1.319.3310.010.54531.295.67257,526.30-7.68-4.32-11.36-5.7713.7114.37-14.09-7.360.7994-1.650.0671---9.790.074131.15--5.71--
Data as of Mar 03 2026. Currency figures normalised to Nicox SA's reporting currency: Euro EUR

Institutional shareholders

0.26%Per cent of shares held by top holders
HolderShares% Held
Erasmus Gestion SASas of 03 Sep 2024190.00k0.22%
Andbank Wealth Management SGIIC SAUas of 31 Dec 202543.30k0.05%
Data from 30 Jan 2026 - 25 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.